{"id":192377,"date":"2018-03-05T02:07:01","date_gmt":"2018-03-05T02:07:01","guid":{"rendered":"http:\/\/www.abnewswire.com\/pressreleases\/?p=192377"},"modified":"2018-03-05T02:07:01","modified_gmt":"2018-03-05T02:07:01","slug":"burns-market-key-players-algipharma-as-cytotools-ag-destiny-pharma-ltd-and-phagelux-inc-analysis-forecast-to-2022","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/burns-market-key-players-algipharma-as-cytotools-ag-destiny-pharma-ltd-and-phagelux-inc-analysis-forecast-to-2022_192377.html","title":{"rendered":"Burns Market Key Players – AlgiPharma AS, CytoTools AG, Destiny Pharma Ltd, and Phagelux Inc Analysis & Forecast to 2022"},"content":{"rendered":"
WiseGuyReports.com with their unique quality of simplifying the market research study presents a deep diving study report \u201cBurns – Pipeline Review, H1 2018\u201d<\/div>\n

Burns<\/a><\/strong><\/p>\n

Overview<\/strong><\/p>\n

A burn is a damage to body’s tissues caused by heat, chemicals, electricity, sunlight or radiation. Symptoms include pain, increasing with each degree of burn, red and swollen skin, blisters and charred and blackened skin. Treatment includes antibiotics and pain relievers.<\/p>\n

Click here for sample report @ https:\/\/www.wiseguyreports.com\/sample-request\/3031084-burns-pipeline-review-h1-2018<\/a> <\/strong><\/p>\n

 <\/strong><\/p>\n

Major Key Players:<\/strong><\/p>\n

American Gene Technologies International Inc<\/p>\n

CFM Pharma Holding BV<\/p>\n

CytoTools AG<\/p>\n

Destiny Pharma Ltd<\/p>\n

Energenesis Biomedical Co Ltd<\/p>\n

Lakewood-Amedex Inc<\/p>\n

Madam Therapeutics BV<\/p>\n

 <\/p>\n

Burns Industry Major Outlook<\/strong><\/p>\n

Pharmaceutical and Healthcare latest pipeline guide Burns    – Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Burns   , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.<\/p>\n

The Burns (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Burns and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies \/Universities \/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND\/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 2, 4, 2, 16, 5 and 3 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.<\/p>\n

Burns pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.<\/p>\n

Burns – Competitive Analysis <\/strong><\/p>\n

Key players are making innovative developments in Burns industry<\/strong>.  The same will help in improving the market performance. Heavy investments are made by major players in the R&D sector<\/p>\n

Scope<\/strong><\/p>\n

The pipeline guide provides a snapshot of the global therapeutic landscape of Burns.<\/p>\n

The pipeline guide reviews pipeline therapeutics for Burns by companies and universities\/research institutes based on information derived from company and industry-specific sources.<\/p>\n

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. <\/p>\n

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.<\/p>\n

The pipeline guide reviews key companies involved in Burns therapeutics and enlists all their major and minor projects.<\/p>\n

The pipeline guide evaluates Burns therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.<\/p>\n

The pipeline guide encapsulates all the dormant and discontinued pipeline projects. <\/p>\n

The pipeline guide reviews latest news related to pipeline therapeutics for Burns.<\/p>\n

.Continued<\/strong><\/p>\n

For Detailed Reading Please visit @<\/strong> https:\/\/www.wiseguyreports.com\/reports\/3031084-burns-pipeline-review-h1-2018<\/a> <\/strong><\/p>\n

 <\/p>\n

About Us <\/strong><\/p>\n

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.<\/p>\n

Contact Us:<\/strong><\/p>\n

NORAH TRENT<\/p>\n

Partner Relations & Marketing Manager<\/p>\n

sales@wiseguyreports.com<\/a><\/p>\n

www.wiseguyreports.com<\/a><\/p>\n

Ph: +1-646-845-9349 (US)<\/p>\n

Ph: +44 208 133 9349 (UK)<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> Wiseguyreports.com
Contact Person:<\/strong> Norah Trent
Email:<\/strong> sales@wiseguyreports.com
Phone:<\/strong> +1 646 845 9349, +44 208 133 9349
City:<\/strong> Pune
State:<\/strong> Maharashtra
Country:<\/strong> India
Website:<\/strong> www.wiseguyreports.com<\/a><\/p>\n

<\/object><\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

WiseGuyReports.com with their unique quality of simplifying the market research study presents a deep diving study report \u201cBurns – Pipeline Review, H1 2018\u201d Burns Overview A burn is a damage to body’s tissues caused by heat, chemicals, electricity, sunlight or … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401],"tags":[],"class_list":["post-192377","post","type-post","status-publish","format-standard","hentry","category-Business"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/192377","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=192377"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/192377\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=192377"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=192377"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=192377"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}